Home oxygen therapy for adults with COPD and ILD: ATS Guidelines

Written By :  Dr. Kamal Kant Kohli
Published On 2020-11-18 03:45 GMT   |   Update On 2020-11-18 08:27 GMT

American Thoracic Society has released latest clinical practice guideline on home oxygen therapy for adults with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). The new guideline was borne out of the 2017 ATS workshop on Optimizing Home Oxygen Therapy data, which "identified the lack of evidence-based clinical practice guidelines for appropriate use of...

Login or Register to read the full article

American Thoracic Society has released latest clinical practice guideline on home oxygen therapy for adults with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD).  

The new guideline was borne out of the 2017 ATS workshop on Optimizing Home Oxygen Therapy data, which "identified the lack of evidence-based clinical practice guidelines for appropriate use of home oxygen as a critical gap," wrote the guideline panel. These guidelines provide the basis for evidence-based use of home oxygen therapy in adults with COPD or ILD but also highlight the need for additional research to guide clinical practice.

The guidelines have been published in the American Journal of Respiratory and Critical Care Medicine.

Further rationale for new guidance came out of "a summary of results from an online survey of almost 2,000 oxygen users in the U.S. describing the multiple problems they had in accessing and using their oxygen," said Susan S. Jacobs, MS, RN, co-chair of the guideline committee and a research nurse manager in Pulmonary, Allergy, and Critical Care Medicine at Stanford University.

"Oxygen is a common, yet burdensome, equipment-laden therapy, so if we are going to prescribe it, there should be enough evidence that we can tell our patients what they should expect in terms of improving their symptoms, and the quality and quantity of their lives," noted Jacobs.

To that end, the multidisciplinary panel used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach to formulate their recommendations summarized below:

COPD Recommendations

  • In adults with COPD who have severe chronic resting room air hypoxemia, we recommend prescribing Long Term Oxygen Therapy (LTOT) at least 15 hours per day (strong recommendation, moderate quality evidence).
  • In adults with COPD who have moderate chronic resting room air hypoxemia, we suggest not prescribing LTOT (conditional recommendation, low quality evidence).
  • In adults with COPD who have severe exertional room air hypoxemia we suggest prescribing ambulatory oxygen (conditional recommendation, moderate quality evidence).

ILD Recommendations

  • For adults with ILD who have severe chronic resting room air hypoxemia we recommend prescribing LTOT at least 15 hours per day (strong recommendation, very low quality evidence).
  • For adults with ILD who have severe exertional room air hypoxemia we suggest prescribing ambulatory oxygen (conditional recommendation, low quality evidence).

Liquid Oxygen Recommendation

  • In patients with chronic lung disease who are mobile outside of the home and require continuous oxygen flow rates of >3L/minute during exertion, we suggest prescribing portable liquid oxygen (conditional recommendation, very low quality evidence).

The guidelines also include a 'best-practice statement' that describes a minimum standard of oxygen education and training for all oxygen users.

The ATS has published nearly 20 clinical practice guidelines on various conditions, ranging from allergy and asthma to TB and other pulmonary infections. For ATS guideline implementation tools and derivatives, go here.

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News